In his latest IPKat post, Darren Smyth “despairs” at the judgment by the Indian Supreme Court in the recent Glivec decision, refusing the patent application directed to imatinib mesylate in beta crystalline form.
Darren says the Court’s failure to understand novelty is an example of what can happen when non-specialist senior courts rule on specialised areas of law.